NCT04345146View on ClinicalTrials.gov

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions

Non-small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT

FSRT combined with Bevacizumab

"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."

Trial Locations (1)

510000

Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT04345146 - Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC | Biotech Hunter | Biotech Hunter